Navigation Links
Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
Date:11/25/2008

AURORA, Ontario, Nov. 25 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") has filed a Form 20-F Registration Statement with the United States Securities and Exchange Commission, to register its common shares with the SEC.

A Form 20-F, once declared effective by the SEC, allows certain foreign corporations to register securities with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. The Company's Form 20-F is a full registration of the Company's common shares with the SEC as a foreign private issuer similar to a Form 10 filing for a domestic issuer in the United States. The Company's registration of its shares in the United States would allow its shares to be solicited and traded by licensed brokers in the United States in compliance with SEC regulations and blue sky requirements in various states in the United States.

"Today's filing is a significant step for the Company toward our goal to enter larger capital markets," said John Docherty, president of Helix BioPharma. "Following effectiveness, we intend to expand our ongoing efforts to grow Helix's corporate profile, with a view to broadening our U.S. investor base and increasing our liquidity."

The Form 20-F is being filed on EDGAR and SEDAR at www.sec.gov/edgar.shtml and www.sedar.com, respectively. Helix anticipates the Form 20-F will be declared effective by the SEC in early 2009, although there is no guarantee that the SEC will declare the filing effective. If the Form 20-F is declared effective by the SEC, the Company will be obligated to file continuous disclosure documentation applicable to foreign private issuers with the SEC following the date the Form 20-F is declared effective.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP."

    For further information contact:

    Investor & Media Relations
    Ian Stone                              Robert Flamm, Ph.D.
    Russo Partners LLC                     Russo Partners LLC
    Tel: (619) 814-3510                    Tel: (212) 845-4226
    Fax: (619) 955-5318                    Email:
    Email:                                 robert.flamm@russopartnersllc.com
    ian.stone@russopartnersllc.com         www.russopartnersllc.com

This News Release contains certain forward-looking statements and information regarding the future registration of Helix's common shares with the U.S. Securities & Exchange Commission and Helix's business, which statements and information can be identified by the use of forward-looking terminology such as "once," "would," "intend to expand," "to grow," "anticipates," "2009," "if," "will be," "developing," or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: uncertainty whether the SEC will declare Helix's Form 20-F effective and Helix's common shares will be registered in the U.S., either in early 2009 or at all; uncertainty whether, even if Helix's common shares are registered, Helix's shares will be actively solicited and traded by licensed brokers in the U.S. or that Helix's liquidity and U.S. investor base will be expanded, which may not occur due to a number of factors including potential lack of demand for Helix's shares, the fact that Helix's shares will be "penny stock" and subject to certain restrictions, and the state of the financial and stock markets generally; uncertainty whether the Company's products under development, including L-DOS47 and Topical Interferon Alpha-2b, will be successfully developed and commercialized as a drug or at all; product liability, insurance and intellectual property risks; research and development risks; the need for further regulatory approvals, which may not be obtained; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with securities regulatory authorities, including its latest Annual Information Form, at www.sedar.com, and Form 20-F at www.sec.gov/edgar.shtml, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 22, 2017 , ... Researchers face a fundamental challenge as ... full-size tissues, bones, even whole organs to implant in people to treat disease ... into the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
(Date:3/22/2017)... 22, 2017 The global chronic ... research report by Transparency Market Research (TMR). The top ... and AbbVie Inc., accounted for a share of only ... in this market are focusing aggressively on mergers, acquisitions, ... is likely to lead to market consolidation in the ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
Breaking Biology Technology:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
Breaking Biology News(10 mins):